Navigation Links
ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Date:10/28/2009

e U.S. For the third quarter of 2009, SG&A increased $5.9 million over the same period in 2008. The largest contributors to this increase were increased compensation costs resulting from expansion of our Cinryze field force, increased marketing efforts and increased professional fees. For the nine months ended September 30, 2009, R&D expenses decreased $0.7 million, driven by decreased costs related to discontinuing the maribavir prophylactic program, offset by the Cinryze open label trials and patient follow-up, manufacturing NTCD spores, and higher compensation costs. For the nine month period, the largest contributors to this $23.8 million increase for SG&A over the nine month period in 2008 were increased compensation costs from the addition of our Cinryze field force, increased marketing efforts, and increased professional fees.

The Company's tax expense for the quarter was $9.6 million and $5.6 million for the quarters ended September 30, 2009 and 2008, respectively and $20.2 million and $19.7 million for the nine months ended September 30, 2009, respectively. Income tax expense includes federal, state and foreign income tax at statutory rates and the effects of various permanent differences.

Working Capital Highlights

As of September 30, 2009, ViroPharma's working capital was $357.9 million, which represents a $30.2 million increase from June 30, 2009 and a $40.5 million increase from December 31, 2008. The nine month increase is primarily the result of net sales, offset by our repurchase of $45 million principal amount of our senior convertible notes. Cash flow provided by operating activities for the nine months ended September 30, 2009 was $41.6 million.

Looking ahead in 2009

ViroPharma is revising its guidance for the year 2009. The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
2. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
3. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
4. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
5. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
6. ViroPharma Announces Discontinuation of HCV-796 Development
7. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
8. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. ViroPharma to Present at the Natixis Bleichroeder Conference
10. ViroPharma to Present at Three Upcoming Healthcare Conferences
11. Accuray Incorporated to Present at 20th Annual Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 17, 2015 Research and ... of the "G-Protein Coupled Receptors Market: Global ... 2014 - 2022" report to their offering. ... been segmented based on of assay type, therapeutic ... GPCRs market has been categorized into six major ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v4wlnk/key_pharma_news ) ... Pharma News Issue" newsletter to their offering. ... burgeoning oncology pipeline and serves as a statement ... in 2015, with a large-scale potentially transformative acquisition ... Key Pharma News covers all major developments in ...
(Date:7/27/2015)... , July 27, 2015 Research and Markets ... "Intraoperative Imaging Market by Type (Intraoperative CT, Intraoperative ... Asia-Pacific, ROW) - Global Forecast to 2019" report ... expected to reach a value of $2.1 Billion by ... of 3.5% during the forecast period. ...
Breaking Medicine Technology:G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 2Key Pharma News Issue - Gilead will make further oncology deals in 2015 2Key Pharma News Issue - Gilead will make further oncology deals in 2015 3Global Intraoperative Imaging (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) Market Forecasts & Trends 2015-2019 2
(Date:7/27/2015)... ... ... With a new charity program in the Chico, CA area, Gary Short ... number of deaths and injuries occurring from police pursuits, and announced that they will ... the police to find better and safer ways to conduct pursuits. To support this ...
(Date:7/27/2015)... , ... July 27, 2015 , ... Throughout its 20 ... premier doctors and medical providers working on a lien basis. As the personal ... wide range of providers from chiropractors, to orthopedists, to pain management physicians, to psychologists ...
(Date:7/27/2015)... ... July 27, 2015 , ... At Champagne Smiles, they know that tooth ... can incur a lot of stress, pain, discomfort and embarrassment, which is why they ... treatment reaps the benefits of implants with the cost savings of dentures for anyone ...
(Date:7/27/2015)... ... July 27, 2015 , ... Recently, 10 Best ... other respected water brands also made the organization’s list. As its name clearly indicates, ... options available. Here is a description of the top three brands, along with a ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... In a ... treatment programs help restore a healthy lifestyle, The Ranch at Dove Tree in Lubbock ... text guide readers easily through the steps of recovery. Both the nationally recognized collegiate ...
Breaking Medicine News(10 mins):Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 2Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 3Health News:Doctors on Liens Adds Highly Respected Physical Therapy Office in Los Angeles 2Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 2Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 4Health News:Best Water Brand Awards Presented by 10 Best Water 2Health News:The Ranch At Dove Tree Infographic Enlightens Process Of Recovery 2Health News:The Ranch At Dove Tree Infographic Enlightens Process Of Recovery 3
... some NSAIDS, it could prevent buildup of plaque in ... News) -- A class of drugs called gamma-secretase modulators ... suggests. , A hallmark of Alzheimer,s is so-called amyloid ... modulators reduce the production of long pieces of amyloid ...
... June 11th 2008: At least 50% of recent onset ... signs and symptoms) within 36 weeks when following a ... tight control, according to results of a study presented ... European League Against Rheumatism in Paris, France. Results of ...
... June 11, 2008 Understanding the way bacterial cells ... methods for fighting the often persistent and serious infections ... A&M University professor of chemical engineering who not only ... quell their conversation. , Examining Escherichia coli bacteria ...
... Addicted, cells provide early diagnosis; diet could affect changes, ... changes in the DNA,s chemical coding may make the bowel ... turning the switch on in abnormal genes, a new study ... published their findings in the current issue of the ...
... British parents are to be quizzed about their children,s sex ... way the subject is taught to deaf pupils. , The ... of both deaf and hearing primary school children for its ... researchers hope their findings will make SRE more accessible for ...
... Potential Salmonella Risk, APTOS, Calif., June 11 ... raw tomatoes due to possible,contamination with salmonella, the ... tomato products,-- such as sauces, soups, paste, ketchup ... to continue enjoy. In processing tomato products, heat,reaches ...
Cached Medicine News:Health News:New Class of Drugs May Fight Alzheimer's 2Health News:New Class of Drugs May Fight Alzheimer's 3Health News:50 percent of recent onset RA patients become free of signs and symptoms within 36 weeks 2Health News:Chemical engineering researchers identify biofilms that cause infections 2Health News:Chemical engineering researchers identify biofilms that cause infections 3Health News:Chemical engineering researchers identify biofilms that cause infections 4Health News:DNA Coding May Make Bowel Prone to Cancer 2Health News:Study aims to improve sex education for deaf pupils 2Health News:Study aims to improve sex education for deaf pupils 3Health News:Clarity Needed Amidst Tomato Contamination Confusion 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: